Sanofi backs Escient’s $77.5M round as it kick-starts first clinical test
Escient Pharmaceuticals has grabbed a meaty $77.5 million series B with the help of Sanofi’s VC arm as the biotech also starts its first in-human tests.
Escient Pharmaceuticals has grabbed a meaty $77.5 million series B with the help of Sanofi’s VC arm as the biotech also starts its first in-human tests.
Heading into a pivotal year in 2021, Forma Therapeutics has hired two veterans out of Takeda and Incyte to help run its R&D programs.
Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or solving problems.
Pfizer has tipped its pipeline to deliver new products that add more than $15 billion to revenues by 2025. The anticipated pipeline contributions led Pfizer to predict it will weather the next wave of patent expirations that is set to start in 2026.
The FDA has rejected Mallinckrodt’s request for approval of terlipressin in a rare type of progressive kidney failure. Mallinckrodt suffered the setback despite hitting its primary endpoint in phase 3 and winning the backing of an advisory committee in a split decision.
A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A.
Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the U.K.
Merck has struck a deal to develop Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin. The agreement will see Merck pay $600 million and make a $1 billion investment in Seattle Genetics in return for the chance to embark on a joint development program.
A year after a positive readout and two years since its series B round, Orasis Pharmaceuticals has raised a further $30 million.
Vaccines get all the headlines, but the use of antibodies to both treat and prevent SARS-CoV-02 infection is an equally major part of the COVID-19 arsenal.